Condition: Breast Cancer Early Stage Breast Cancer (Stage 1-3) · HER2 · Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
The goal of this observational study is to assess the prognostic value of a genomic classifier (S18) and its refined version (S\*) in women with early-stage HER2-positive breast cancer. The study aims to determine whether these tools can predict event-free (EFS) and disease-free survival (DFS) in patients treated with neoadjuvant and/or adjuvant trastuzumab-based therapies.
This description comes directly from the study's public registry record.
Serena Di Cosimo, MD, PhD · +39 02 2390 2700 · serena.dicosimo@istitutotumori.mi.it
Paolo Verderio, PhD · +39 02 2390 3201 · paolo.verderio@istitutotumori.mi.it
Always discuss trial participation with your own doctor first.
| Ospedale Di Summa-Perrino | Brindisi, Italy | Recruiting |
| Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale | Naples, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06762977